Shares of Novo Nordisk A/S (NYSE:NVO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $145.17.
Several analysts recently weighed in on NVO shares. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Argus boosted their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Monday, August 19th. Finally, The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price for the company.
Get Our Latest Report on Novo Nordisk A/S
Hedge Funds Weigh In On Novo Nordisk A/S
Novo Nordisk A/S Trading Up 4.2 %
NYSE:NVO opened at $135.17 on Thursday. The firm has a market capitalization of $606.58 billion, a P/E ratio of 46.61, a P/E/G ratio of 1.43 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The company has a fifty day moving average of $134.18 and a 200 day moving average of $132.75. Novo Nordisk A/S has a 52 week low of $86.96 and a 52 week high of $148.15.
Novo Nordisk A/S (NYSE:NVO – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The business had revenue of $9.82 billion for the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. On average, research analysts predict that Novo Nordisk A/S will post 3.11 earnings per share for the current year.
Novo Nordisk A/S Cuts Dividend
The business also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were issued a $0.5126 dividend. This represents a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 24.83%.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
- Five stocks we like better than Novo Nordisk A/S
- Dividend Capture Strategy: What You Need to Know
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Investing in the High PE Growth Stocks
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.